HEMEMICS Biotechnologies, Inc. Receives HHS Support to Develop Rapid Antigen, Antibody Diagnostic to Identify COVID-19 Infected Americans
Rapid Testing and Cloud-based Networking Allow Real-Time Outbreak Alerts for Health Agencies
Hememics Biotechnologies Received $2.5 Million Investment from AMVI Partners
Vietnamese Investors Back Novel Point-of-Care Technology for Rapid Detection of Pathogens
HEMEMICS' technology can rapidly transform the $6B blood culture and $20B immunoassay testing markets.
To find out more about how the HEMEMICS technology can uniquely address COVID-19 and other diagnostic challenges, contact us.